

To: European Commission
Health and Consumer Protection
Directorate-General
Rare Diseases consultation
HTC 01/198
11, Rue Eugène Ruppert
L-2557 Luxembourg

ZNA Koningin Paola Kinderziekenhuis

Lindendreef 1 2020 Antwerpen

tel. 03 280 3111 www.zna.be

datum February 12, 2008

o. ref FE/mpt

Concerning: Response to consultation for Rare Diseases



geneesheer-directeur
prof. dr. F. Eyskens
tel. 03 280 21 36
francois.eyskens@zna.be

medisch secretariaat
tel. 03 280 21 37
fax. 03 280 21 33

diëtisten
Sigrid Beernaert
An Desloovere
Inneke Verbergt
tel. 03 280 21 38
mi.dieetafdelingCEMA@zna.be

verpleegkundige
Ann Neirinck
tel. 03 280 20 10-11

sociaal verpleegkundige
Piet Van Camp
tel. 03 280 21 10

klinische psychologen
Ikram Meskal
An Coetsiers
tel. 03 280 49 41

kinder- en jeugdpsychiater
dr. A. Simons
tel. 03 280 49 00

satellietdienst
UZ Antwerpen
geneesheer-directeur
prof. dr. F. Eyskens
tel. 03 821 38 10

diëtiste
Nancy Pyck
tel. 03 821 34 01

Metabool labo
Provinciaal
Centrum voor opsporing van
Metabole
Aandoeningen
tel. 03 740 50 20

Madame, Sir,

In response to the European Commission's consultation for Rare Diseases, we wish to present the *Middelheim's Team for Orphan Diseases* (MITOD).

This multidisciplinary team consists of medical doctors with expertise in the field of rare metabolic disorders, especially Fabry's disease. In order to optimize the diagnostic and therapeutic approach of this patient group, the team meets on a monthly basis to discuss the management of each individual patient using a diagnostic and therapeutic protocol based on current international guidelines.

Besides providing optimal medical care, we put efforts in clinical research. We initiated and currently participate in epidemiological studies on the prevalence of Fabry's disease on a regional, national and international level and we enter our patient data in international Fabry registers, in order to improve current knowledge of this rare disease.

In the near future we will invite other experts in rare diseases (e.g. Gaucher disease, Pulmonary Hypertension, MPS,...) that are active in our institution and the University Hospital of Antwerp (e.g. Pompe disease) to join us in a clinical and scientific board.

Yours sincerely,

Prof. Dr. P.P. De Deyn
Chief Dept. Of Neurology
ZNA Middelheim

Prof. Dr. F. Eyskens
Dept. Of Metabolic Diseases
Queen Paola Child Hospital

Dr. R. Brouns
Dept. of Neurology
ZNA Middelheim

Dr. K. De Boeck
Dept. of Nephrology
ZNA Middelheim

Prof. Dr. G. De Keulenaar
Dept. of Cardiology
ZNA Middelheim

This paper represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumer Protection DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.